Launches And International Sales Propel Growth For Teligent Despite Bumpy Year

In 2018, product launches and growth in International sales enabled Teligent to post a group sales rise of almost a tenth to US$65.9 million, despite price erosion and serialization requirements impacting the business. Teligent expects its expanded US manufacturing facility in Buena, New Jersey, to be inspected by the FDA in the first half of 2019, with its first injectable to be launched from the site by the end of the year.